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Background: Cucurbitacin B, an oxygenated tetracyclic triterpenoid compound extracted from the Thai medicinal
plant Trichosanthes cucumerina L., has been reported to have several biological activities including anti-inflammatory,
antimicrobial and anticancer. Cucurbitacin B is great of interest because of its biological activity. This agent inhibits
growth of various types of human cancer cells lines.
Methods: In this study, we explored the novel molecular response of cucurbitacin B in human breast cancer cells,
MCF-7 and MDA-MB-231. The growth inhibitory effect of cucurbitacin B on breast cancer cells was assessed by MTT
assay. The effects of cucurbitacin B on microtubules morphological structure and tubulin polymerization were analyzed
using immunofluorescence technique and tubulin polymerization assay kit, respectively. Proteomic analysis was used
to identify the target-specific proteins that involved in cucurbitacin B treatment. Some of the differentially expressed
genes and protein products were validated by real-time RT-PCR and western blot analysis. Cell cycle distributions and
apoptosis were investigated using flow cytometry.
Results: Cucurbitacin B exhibited strong antiproliferative effects against breast cancer cells in a dose-dependent
manner. We show that cucurbitacin B prominently alters the cytoskeletal network of breast cancer cells, inducing rapid
morphologic changes and improper polymerization of the microtubule network. Moreover, the results of
2D-PAGE, real-time RT-PCR, and western blot analysis revealed that the expression of nucleophosmin/B23 and c-Myc
decreased markedly after cucurbitacin B treatment. Immunofluorescence microscopy showed that cucurbitacin B
induced translocation of nucleophosmin/B23 from the nucleolus to nucleoplasm. Treatment with cucurbitacin B
resulted in cell cycle arrest at G2/M phase and the enhancement of apoptosis.
Conclusions: Our findings suggest that cucurbitacin B may inhibit the proliferation of human breast cancer cells
through disruption of the microtubule network and down-regulation of c-Myc and nucleophosmin/B23 as well as the
perturbation in nucleophosmin/B23 trafficking from the nucleolus to nucleoplasm, resulting in G2/M arrest.
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Cancer is the leading cause of death worldwide, account-
ing for 7.6 million deaths in 2008 [1]. The incident rate
of cancer continues to increase largely due to the aging
and growth of the world population and an increasing
adoption of cancer-causing behaviors, particularly smok-
ing, in developing countries [2]. Breast cancer is the
most common cancer and the leading cause of cancer
deaths among women in all races [3]. This cancer is usu-
ally treated with surgery and chemotherapy or/and radi-
ation. However, undesired side effects may occur during
breast cancer treatment [4,5]. Alternative medicine, such
as the use of medicinal plants and derived natural pro-
ducts in cancer treatment, may reduce adverse side
effects. The scientific evidence on the efficacy and safety
still remains limited.
Cucurbitacins, oxygenated tetracyclic triterpenoid
compounds extracted from cucurbitaceae plants, have
been reported to have anti-inflammatory, antimicrobial
and anticancer activities [6,7]. Cucurbitacins are classi-
fied into cucurbitacin A, B, C, D, E, F, I, L, 23,
24-dihydrocucurbitacin F, and hexanocucurbitacin F, as
well as the three acetylated derivatives [8]. Among these
compounds, cucurbitacin B is the most abundant form
of cucurbitacins (Figure 1). Recently, it has been
reported that cucurbitacin B inhibits growth of various
types of human cancer cells and tumor xenografts. For
instance, cucurbitacin B inhibits the proliferation of mel-
anoma cells by inducing rapid depletion of the G-actin
pool through ROS-dependent actin aggregation [9].
Moreover, cucurbitacin B inhibits both the STAT3 acti-
vation and the Raf/MEK/ERK pathway in K562 leukemia
cell [10]. Chan et al. (2010) demonstrated that cucurbita-
cin B effectively restrains liver cancer xenograft through
oral administration and this anticancer activity is contri-
butable to the suppression of c-Raf and activation of
ERK1/2 [11]. Previous studies also revealed that cucurbi-
tacin B markedly inhibits growth of cancer cells andFigure 1 Chemical structure of cucurbitacin B (25-acetoxy-
2β,16α,20β-trihydroxy-9β-methyl-19nor-10α-lanosta-5,23-diene-
3,11,22-trione).affects their cytoskeletal network [12,13]. Therefore,
cucurbitacin B could probably affect the dynamics of
microtubule stabilization.
Microtubule, a component of the cytoskeleton, is a dy-
namic heterodimer of α-tubulin and β-tubulin subunit.
It plays crucial roles in various fundamental cell func-
tions, including mitotic regulation, maintenance of cell
morphology, intracellular motility and macromolecules
and organelles trafficking [14,15]. Since microtubule is
extremely essential for the process of mitosis, disruption
of this structure can inhibit mitotic spindle regulation,
arrest cell cycle progression at mitosis, and eventually
lead to apoptosis [16,17]. There are two main types of
microtubule-antimitotic targeted drugs used for treat-
ment of highly proliferative malignant cells. Microtubule
stabilizing drugs such as paclitaxel bind to β-tubulin and
stabilize microtubules which could reduce their dynami-
city, promote mitotic arrest and induce cell death
[18,19]. Vincristine, a microtubule-destabilizing drug,
binds to tubulin and inhibits microtubule formation,
resulting in disruption of spindle assembly and arrest
cell cycle at M phase [20,21].
In this work, we further explored the molecular mech-
anism response for cucurbitacin B isolated from Thai
medicinal plant, Trichosanthes cucumerina L. in human
breast cancer cells. Our data show that cucurbitacin B
exhibits strong antiproliferative effects against breast can-
cer cells through disruption of microtubule polymerization
and induces nucleophosmin/B23 translocation, causing
cell cycle arrest at G2/M phase and induces apoptosis of
breast cancer cells.
Methods
Cell lines and drug preparation
Human breast cancer cell lines (MDA-MB-231 (ER-, p53-),
and MCF-7 (ER+, p53+)) were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM/F12, Gibco, Grand
Island, NY) supplemented with 10% fetal bovine serum
(FBS, Gibco, Grand Island, NY), 100 U/mL penicillin and
100 μg/mL streptomycin (Gibco, Grand Island, NY) at
37°C in a humidified 5% CO2 incubator. Cells used in the
study were in the exponential phase. Cucurbitacin B was
obtained from the well known plant species,Trichosanthes
cucumerina L. Briefly, the fruits of C. cucumerina, after
ripening and became air-dry naturally, were collected
from Nakhon Sawan province, Thailand. A voucher speci-
men of the plant and a dry fruit (Kimyong Chokepaiboon
No. 002) are deposited at the Faculty of Science,
Ramkhamhaeng University. The peels and seeds were
removed to leave the fruit fibers, which were cut into
small pieces and extracted successively with n-hexane
and ethyl acetate. Column chromatography of the
ethyl acetate extract gave, after recrystallization, pure
cucurbitacin B as the major component Additional
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and mass spectra) data were consistent with its struc-
ture and with the reported data [8]. This compound
was dissolved in 10% dimethyl sulfoxide (DMSO) and
diluted with DMEM/F12. Twenty-four hours after
seeding, cucurbitacin B was added to the fresh culture
medium to a various specified final concentration.
Cells were incubated with cucurbitacin B for indicated
times.
MTT assay
The growth inhibitory effect of cucurbitacin B on breast
cancer cells was assessed by the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT, Chemicon,
Billerica, MA) assay. Cells (1×104 cells/well) were seeded
in 96-well plate and allowed to attach the well overnight.
Cucurbitacin B was added to a final concentration
(0.1, 1, 10, 100 μM) and the cells were incubated for fur-
ther 48 hr. After incubation, 10 μl of 5 mg/mL MTT
was added to the cells for 4 hr at 37°C. Afterthen, 100 μl
isopropanol in 0.04 N HCl was added as the solubilizing
agent. The absorbance at 570 nm was read using a
microplate reader (Beckman coulter, Mississauga, ON)
and the proportion of cell survival was calculated by div-
iding the average absorbance of the treated cells by the
average of untreated cells. All experiments were per-
formed in triplicate.
Tubulin polymerization assay
The effect of cucurbitacin B on tubulin polymerization
was analyzed using the Tubulin Polymerization Assay
Kit (Cytoskeleton, Denver, CO). The assay was per-
formed following the manufacturer’ guidance. Briefly,
bovine brain tubulin protein was diluted with 420 μl of
tubulin polymerization buffer containing 80 mM PIPES
pH6.9, 2 mM MgCl2, 0.5 mM EGTA, 1 mM GTP, 10.2%
glycerol to give a final concentration of 3 mg/mL tubu-
lin. Then, the diluted tubulin was transferred to the pre-
warm 96-well plate that contains 10 μl of cucurbitacin B
(2.5, 5, and 10 μM), paclitaxel (10 μM), vincristine
(10 μM), or vehicle (tubulin minus compound control).
The polymerization of tubulin was measured at each
consecutive minute during a period of 30 minutes at
37°C using the VarioSkan Flash microplate reader
(Thermo, Helsinki, Finland) set at 340 nm.
Cell cycle analysis
Cell cycle distribution was analyzed by flow cytometry.
Cells (1x106 cells/well) were treated with cucurbitacin B
at various concentrations for 24 hr and harvested. The
cells were trypsinized and resuspended in 1ml Dulbec-
co's Phosphate-Buffered Saline (DPBS). One million cells
were centrifuged and suspended in 0.5 ml of Krishan re-
agent (0.1% Na citrate, 0.03% NP-40, 0.05 mg/mLPropidium iodide (PI), 0.02 mg/mL RNase A) before
analysis. The stained cells were subjected to DNA con-
tent/cell cycle analysis using an LSR flow cytometer (BD
Biosciences, Franklin Lakes, NJ) and analyzed using
FlowJo software (Tree Star, Ashland, OR).Apoptosis analysis
The Annexin V–FITC Apoptosis Detection Kit (BD bio-
science, Bedford, MA) was used to assess Annexin
V-positive cells. Briefly, cells (1x106 cells/well) were trea-
ted with cucurbitacin B at various concentrations for
24 hr and harvested. The freshly prepared cells were
incubated with 1x Annexin binding buffer and Annexin
V–FITC (2.5 μg/mL)-conjugated primary antibody for
15 min on ice. After incubation, 10 μg/mL PI was added
to the suspension and the cells were measured by flow
cytometry using an LSR flow cytometer (BD Biosciences,
Franklin Lakes, NJ) and analyzed using FlowJo software
(Tree Star, Ashland, OR).Proteomic analysis
Cells (5×105 cells/well) were seeded into 6-well plates
and treated with cucurbitacin B at various concentra-
tions for 48 hr. Cell pellets were collected and lysed with
100 μl RIPA cell-lysis buffer (50 mM Tris pH 8.0,
150 mM NaCl, 0.1% SDS, 0.5% Na Deoxycholate, 1%
TX-100) plus 1 mM NaF, 10 mM NaVO4, 10 mM PMSF,
and 1/100 protease inhibitor cocktail (Sigma, St. Louis,
MO). Protein extracts were separated according to their
isoelcetric point (pI) followed by their molecular weight.
Seven centimeter IPG strip (Bio-Rad, Hercules, CA)
was rehydrated in 125 μl rehydration buffer contain-
ing 100μg protein samples for 16–24 hr at room
temperature. Isoelectricfocusing was performed at 20°C
with a limiting current 50 μA/IPG strip using the follow-
ing parameter: 250 V for 20 min, 4,000 V for 2hr, 4,000
V for 10,000 V-hr. Focused gel was equilibrated for
10 min in 10 mL of Equilibration buffer I (6 M urea,
0.375 M Tris–HCl, pH 8.8, 2% SDS, 20% glycerol, 2%
DTT) and 10 min in Equilibration buffer II (6 M urea,
0.375 M Tris–HCl, pH 8.8, 2% SDS, 20% glycerol, 2.5%
iodoacetamide). For the second dimension, focused pro-
tein on IPG strip was separated on 12.5% polyacrylamide
gel. Electrophoresis was performed at 20 mA/gel for the
first 10 min following by 40 mA/gel. Gel was stained
with Coomassie Brilliant Blue R-250 (Bio-Rad, Hercules,
CA). The protein spots were excised from the stained
gel and analyzed by LC-MS/MS mass spectrometer to
obtain a mass peptide fingerprint. For identification of
proteins, the peptide mass fingerprinting data were used
to search in databases using Mascott program (Matrix
Science, London, UK). The peptide mass fingerprinting


























Figure 2 Cucurbitacin B inhibits growth of human breast
cancer cells. MCF-7 and MDA-MB-231 were treated with
cucurbitacin B at a final concentration, ranging from 0 to 100 μM for
48 hr. Growth inhibition was determined by the MTT assay. The
percentage of cell survival was calculated by defining the absorption
of cells without cucurbitacin B treatment as 100%. Results are the
average of three independent experiments *, p<0.05 (treated vs
untreated control).
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RNAs were extracted from the cells then the levels of
mRNA of each gene (including c-Myc, STAT3,
NUCLEOPHOSMIN/B23, and Tubulin) were deter-
mined by real-time RT-PCR. In brief, cells (5x105 cells/
well) were seeded into 6-well plate and treated with vari-
ous concentration of cucurbitacin B for 48 hr. Total
RNA was isolated from each cell line using the Qiagen
RNeasy Mini Kit (Qiagen, Valencia, CA). Two micro-
grams of total RNA were reverse-transcribed with
random primer according to the manufacture’s proto-
col using High-Capacity cDNA Reverse Transcription
kit (Applied Biosystems, Foster City, CA). Real-time
PCR was performed using Fast SYBR Green Master
Mix (Applied Biosystems, Foster City, CA) with the
Applied Biosystems 7500 Fast Real-Time PCR system
(Applied Biosystems, Foster City, CA). The relative ratio
of each gene was then calculated using the formula:
2-ΔΔCt = 2- {ΔCt(Cucurbitacin B-treated) - ΔCt(untreated)}, where
ΔCt=Ct(Genes)-Ct(GAPDH).
Western blot analysis
Cells (1x106 cells/well) were treated with various con-
centration of cucurbitacin B for 48 hr. The cell pellets
were collected and lysed with 100 μl RIPA cell-lysis buf-
fer (50 mM Tris pH 8.0, 150 mM NaCl, 0.1% SDS, 0.5%
Na deoxycholate, 1% TX-100) plus 1 mM NaF, 10 mM
NaVO4, 10 mM PMSF, and 1/100 protease inhibi-
tor cocktail (Sigma, St. Louis, MO). Total protein
was determined using Bio-Rad protein assay (Life
science, Hercules, CA). Proteins were separated by
12.5% SDS-Polyacrylamide gels and electrotransferred
onto nitrocellulose membranes before treating overnight
with anti-nucleophosmin/B23, anti-STAT3, anti-tubulin,
and anti-c-Myc (Santa Cruz Biotechnology, Santa Cruz,
CA). Equal protein loading was confirmed on all immu-
noblots using GAPDH antibody (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA). Goat anti-rabbit IgG and goat
anti-mouse IgG (BD Transduction Laboratories, San
Diego, CA) were used as secondary antibodies against all
primary antibodies. Protein bands were visualized by
chemiluminescence with ECL plus reagent (Pierce, Rock-
ford, IL) on a Typhoon FLA 7000 fluorescent detection
system (GE Healthcare, Piscataway, NJ).
Localization of nucleophosmin/B23
Cells (1x105 cells/well) were seeded on cover slips in a
6-well plate overnight at 37°C. After removing the
medium, the cells were treated with cucurbitacin B for
20 min and fixed with 4% formaldehyde in PBS for
30 min. Fixed cells were permeabilized with 0.5% Triton
X-100 in PBS for 10 min, blocked in 2% BSA in PBS for
30 min, and washed three times in PBS. The cover slip
was stained with anti-nucleophosmin/B23 antibody(Santa Cruz Biotechnology, Santa Cruz, CA) in blocking
buffer for 1 hr, washed 3 times with PBS, and incubated
with Alexa 568-conjugated anti-mouse IgG rabbit anti-
body (Molecular Probes, Eugene, OR) for an additional
hour. DAPI dilution 1:1000 in PBS was used for nuclear
staining (Sigma, St. Louis, MO). The cover slip was
mounted with 50% glycerol in PBS on glass slide and
sealed. The slide was visualized under Zeiss LSM 710 con-
focal microscopy (BD Biosciences, Franklin Lakes, NJ).
Immunofluorescence detection of microtubules
The effect of cucurbitacin B on microtubules morpho-
logical structure was visualized by immunofluorescence
microscopy. Cells (1x105 cells/well) were seeded on
cover slips in a 6-well plate overnight as mentioned
above, treated with cucurbitacin B for 15 min and fixed
with 4% formaldehyde in PBS for 30 min. Fixed cells
were permeabilized, blocked, and washed as described
above. Cover slip was stained with monoclonal anti-
tubulin antibody dilution 1:500 in blocking buffer (Santa
Cruz Biotechnology, Santa Cruz, CA) for 1 hr, washed 3
times with PBS and stained with 488 goat anti-rabbit
IgG secondary antibody dilution 1: 5,000 in blocking
buffer (Molecular Probes, Eugene, OR) for 1 hr. After
washing with PBS, the cover slip was stained with DAPI
dilution 1:1000 in PBS (Sigma, St. Louis, MO). The
stained cover slip was mounted with 50% glycerol in
PBS on glass slide and sealed. The slide was visualized
under Zeiss LSM 710 confocal microscopy (BD Bios-
ciences, Franklin Lakes, NJ).
Statistic analysis
All experiments were performed in triplicate. Statistical
analysis was analyzed using one-way ANOVA to
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B) and treated cells. P value < 0.05 was considered statis-
tically significant.
Results
Cucurbitacin B exhibited antiproliferative activity against
human breast cancer cells
To investigate the effect of cucurbitacin B on the pro-
liferation of human breast cancer cells. MCF-7 and
MDA-MB-231 cells were treated with the specified con-
centrations of cucurbitacin B for 48 hr. Cell viability was
determined by MTT proliferation assay. The percentage
of viability was calculated by defining the absorption of
cells without cucurbitacin B treatment as 100%. Results




























Figure 3 Effect of cucurbitacin B on cell-cycle distribution. MCF-7 and
24 hr, and then stained with propidium iodide (PI) before subjected to flow
represent the cell population at each cell cycle phase as determined by th
Blockage at G2/M and apoptotic induction was observed. B. The values ind
(treated vs untreated control).Cucurbitacin B extracted from the fruit fiber of
T. cucumerina L. exhibited a dose-dependent inhibitory
effect with the IC50 (mean inhibitory concentration that
inhibited 50% growth) of 4.12 μM and 3.68 μM for
MCF-7 and MDA-MB-231, respectively, as demon-
strated in Figure 2. However, p53-mutant ER-/PR- and
Her2- (triple-negative) MDA-MB-231 cell was more
sensitive to cucurbitacin B than MCF-7.
Cucurbitacin B caused cell cycle arrest at G2/M phase and
induced apoptosis of breast cancer cells
MCF-7 and MDA-MB-231 cells were treated with
2.5 μM and 5 μM cucurbitacin B for 24 hr, then stained
with PI and subjected to flow cytometric analysis. The





















MDA-MB-231 were treated with 0, 2.5, and 5 μM cucurbitacin B for
cytometric analysis. A. The cell cycle/DNA content histograms
e level of DNA content in each cucurbitacin B treatmented group.
icate percentage of cells in each phases of the cell cycle. *, p<0.05


































Figure 4 Apoptotic induction by cucurbitacin B. MCF-7 and MDA-MB-231 were incubated with cucurbitacin B for 24 hr and apoptosis was
analyzed by Annexin V-FITC. A. Annexin V-FITC staining is represented on the X-axis and PI staining is represented on the Y-axis. B. The values
indicate the percentage of apoptotic cells in each concentration. Results shown are the average of three independent experiments. *, p<0.05
(treated vs untreated control).




MW/pI Protein identified Expression
CuB1 gi/825671 28/4.41 Nucleophosmin/B23 Down-regulated
CuB2 gi/31542947 61/5.59 Chaperonin Up-regulated
CuB3 gi/20070125 57/4.61 Prolyl 4-hydroxylase Up-regulated
CuB4 gi/16507237 72/4.92 Heat shock 70kDa Up-regulated
Protein identification from 2-D gel.
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were observed in cucurbitacin B-treated cells. The trea-
ted cells were arrested at the G2/M phase of the cell
cycle in both cell lines with decreased cell population in
G1 and S phase (Figure 3). Moreover, the percentage of
G2/M phase in cucurbitacin B-treated MDA-MB-231
cells is higher than in MCF-7 cells. The increase of cell
in subG1 phase shown in the DNA histogram is the in-
dicative of DNA fragmentation and apoptosis. Apoptosis
was confirmed by staining the phosphatidylserine trans-
location with Annexin V-FITC. Results in Figure 4 indi-
cated that cucurbitacin B treatment for 24 hr
significantly induced apoptosis approximately 30% to
40% of breast cancer cells population.
Determination of protein changes by cucurbitacin B
treatment in breast cancer cells
The expression of target-specific proteins that are
unique to the effect of cucurbitacin B in human breast
cancer cells was determined by two-dimentional gelelectrophoresis. Total proteins from untreated-cells and
treated-cells were separated according to their isoelectric
point (pI) and molecular weight (MW). Four separated
peptide spots that showed significant changes in cucur-
bitacin B-treated cells compare to untreated cell were
selected (Additional file 2). The proteins were identified
by LC-MS/MS. As shown in Table 1, the result reveals
that among the three proteins whose expressions were
up-regulated, two of them, Hsp70 and β-subunit of pro-
lyl 4-hydroxylase, belong to the heat shock protein class
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[22,23]. This might include the stress induced by cucur-
bitacin B. Of the four identified proteins, nucleophos-
min/B23, an important nucleolar phosphoprotein was
down-regulated. This protein functions in various cellu-
lar processes, such as ribosome biogenesis, centrosome
duplication, cell cycle progression, apoptosis and cell dif-
ferentiation [24].
To validate the identified proteins of interest, we per-
formed real-time PCR and western blot analysis in order
to determine the expression levels of these proteins in
MCF-7 and MDA-MB-231 cells. Cells were incubated
for 48 hr with the specified concentrations of cucurbita-
cin B and RNAs were extracted for real-time PCR to
quantitate the expression levels of genes. After cucurbi-
tacin B treatment, the expression of nucleophosmin/B23
and c-Myc gene was decreased in dose-dependent man-
ner but the decrease was not seen for STAT3 and tubu-
lin in both cell types as shown in Figure 5A. The protein
expressions of nucleophosmin/B23 and c-Myc were alsoFigure 5 Effect of cucurbitacin B on the level of nucleophosmin/B23,
were treated with 0, 2.5, and 5 μM cucurbitacin B for 48 hr. A. RNA was ext
nucleophosmin/B23, STAT3, tubulin, and c-Myc after cucurbitacin B treatme
*, P < 0.05 (treated vs untreated control) B. Western blot was analyzed for pdecreased in dose-dependent manner but STAT3 and
tubulin were not significantly different from the control
in both cell lines, as demonstrated in Figure 5B.
Cucurbitacin B induced nucleophosmin/B23 translocation
from the nucleoli to the nucleoplasm
To study the localization of nucleophosmin/B23 after
cucurbitacin B treatment, cells were seeded on cover slips
in six-well plate and treated with cucurbitacin B for 20
min. The cells were stained with anti-nucleophosmin/B23
antibody and analyzed with confocal microscopy. Figure 6
shows the cellular localization of nucleophosmin/B23 dur-
ing cucurbitacin B treatment. Interestingly, nucleophos-
min/B23-translocation was observed during cucurbitacin
B treatment. The high intensity of nucleophosmin/B23
fluorescence was observed mainly within the nucleoli
region of the untreated control cells and the intensity
was weak in nuclear matrix region. After cucurbitacin
B treatment, the distribution of nucleophosmin/B23
was significantly altered. The fluorescent intensitySTAT3, tubulin, and c-Myc expression. MCF-7 and MDA-MB-231
racted for real-time RT-PCR to quantitate the gene expression levels of
nt. Results shown are the average of three independent experiments.
rotein expression. GAPDH was used as loading control.























Figure 6 Cucurbitacin B changes nucleophosmin/B23 localization in human breast cancer cells. MCF-7 and MDA-MB-231 cells were
stained with anti-nucleophosmin/B23 primary antibody. Alexa 568-conjugated anti-mouse IgG rabbit antibody was used as secondary antibody.
DAPI was used for nuclear localization. Stained cells were analyzed by using confocal microscope. After exposure to 2.5 μM cucurbitacin B for
20 min. Translocation of nucleophosmin/B23 from nucleolus (red) to nucleoplasm (green) was observed.
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the strong fluorescence was observed in nuclear
matrix outside nucleolus. Hence, cucurbitacin B
induced nucleophosmin/B23 translocation from nucle-
olus to nucleoplasm.
Cucurbitacin B caused aggregation of α-tubulin
Treatment of MCF-7 and MDA-MB-231 cells with
cucurbitacin B showed the rapid and dramatic morpho-
logical changes including cell shrinkage and rounding
of the cell shape under light microscope speculation
(Figure 7), pointing to the possibility of microtubule
network disruption. To study the effect of cucurbitacin
B on the structure organization of cellular microtu-
bules, MCF-7 and MDA-MB-231 cells were seeded on
cover slips in six-well plate and treated with cucurbita-
cin B for 15 min. Cells were stained with anti-α-tubulin
antibody. DAPI was used for nuclear staining and then
analyzed by using confocal microscope. Figure 8A shows
the microtubules network in untreated control cells which
display intact organization and arrangement. Compared
with the control cells, cucurbitacin B treated cellsexhibited obvious aggregation of α-tubulin. The changes
were observed within 15 min during incubation with
cucurbitacin B.
We further determined whether cucurbitacin B could
inhibit microtubule assembly in vitro using tubulin
polymerization assay kit in cell-free system. Bovine brain
tubulin was mixed with 2.5 μM, 5 μM, and 10 μM
cucurbitacin B and then monitored the effect of cucurbi-
tacin B on polymerization of tubulin at 340 nm micro-
plate reader as described. The result in Figure 8B shows
that cucurbitacin B did not disrupt the polymerization of
bovine tubulin even in the maximum concentration of
cucurbitacin B, suggesting that cucurbitacin B does not
act directly on microtubule assembly, which is different
from the effects of paclitaxel and vincristine, antimicro-
tubules drugs.
Discussion
Trichosanthes cucumerina L. (Cucurbitaceae family), com-
monly found in Southeast Asia and Australia, is tradition-
ally used for the treatment of helmintic, diabetic and












Control 2.5 uM CuB
Figure 7 Morphological changes by cucurbitacin B treatment of breast cancer cells. MCF-7 and MDA-MB-231 cells were treated with
2.5 μM cucurbitacin B for 24 hr, and the cells were visualized under phase-contrast microscopy to investigate the morphological alteration.
Shrinkage and rounding of the cell shape were observed in both cell types.
Duangmano et al. BMC Complementary and Alternative Medicine 2012, 12:185 Page 9 of 12
http://www.biomedcentral.com/1472-6882/12/185that both root extract and fruit juice of T. cucumerina have
cytotoxic effect against various types of human cancer
cells [25]. Cucurbitacin B, one of the most abundant
forms of cucurbitacins extracted from the fruit
of T. cucumerina, is known for its strong anti-
cancer activity. Our previous studies have shown that
cucurbitacin B exerts anticancer effect by inhibiting
telomerase via down regulation of both the hTERT
and c-Myc [26]. The cell cycle arrest at G2/M phase and
apoptotic induction through the reduction of Wnt asso-
ciated proteins by cucurbitacin B were shown. In addition,
reduced translocation of galactin-3-mediated β-catenin to
the nucleus in breast cancer cells by this agent has been
reported [27]. Noteworthy, cucurbitacin B showed only a
slight effect on the proliferation of a non-malignant HBL-
100 cells [26,27]. We further examined the alternative
mechanism of cucurbitacin B on human breast cancer
cells inhibition in aggressive cancer cell types in which the
treatment is problematic. The MDA-MB-231 was chosen
for study since this cell type exhibits highly aggressive,
triple negative characteristic.
Recently, the effects of cucurbitacin B on cytoskeletal
network have been reported. Haritunians et al. (2008)
showed that cucurbitacin B prominently alters the cyto-
skeletal network of leukemic cells by induces improper
polymerization and subsequent aggregation of F-actin
[28]. Treatment of human glioblastoma multiforme
(GBM) cells with cucurbitacin B significantly changed
their morphology, causing F-actin to be clumped. The
cells were then rounded and refractiled and themicrotubule assembly was disorganized [12]. Similarly,
we show that exposure to cucurbitacin B could cause
shrinkage and rounding of the cell shape (Figure 7).
These morphological changes are hallmark features of
apoptosis, indicating that cucurbitacin B induces apop-
tosis in human breast cancer cells. Our result also indi-
cates that cucurbitacin B is able to induce cell arrest at
G2/M phase of the cell cycle and finally triggers apoptosis
in the two breast cancer cells tested (Figure 3 and
Figure 4).
Since the formation of spindle fibers for chromosome
separation during mitosis is critical to the G2/M transi-
tion process, disruption of spindle function by drug-
induced suppression of microtubule dynamics could
block cell cycle progression at the G2/M phase [14]. As
indicated by immunoflourescent staining (Figure 8A),
disruption of the microtubule network after cucurbitacin
B treatment was observed herein. Cucurbitacin B-treated
cells became more spherical and exhibited aggregation
of α-tubulin. Normal filamentous organization of micro-
tubules were scarcely observed after treatment with
2.5 μM of cucurbitacin B. This finding suggests that
cucurbitacin B disrupts tubulin polymerization to micro-
tubule in the cells. However, our data reveals that
cucurbitacin B might not bind directly to tubulin or
microtubules. Adding paclitaxel into the reaction clearly
demonstrated the increase in tubulin polymerization,
whereas adding vincristine provided the opposite result
as the drug decrease tubulin polymeric intensity. Sur-
prisingly, in this cell-free system cucurbitacin B solely











Figure 8 Cucurbitacin B inhibits microtubule polymerization. A. Effect of cucurbitacin B on the organizations of cellular microtubule network.
Immunofluorescent staining for α-tubulin was inspected in MCF-7 and MDA-MB-231 cells treated with cucurbitacin B. Cells were fixed,
permeabilized and stained with anti-α-tubulin monoclonal antibody. The cells were analyzed using confocal microscopy. DAPI was used for
nuclear localization. Change of tubulin organization within the cells was observed after cucurbitacin B treatment. B. Effect of cucurbitacin B on
microtubule polymerization in a cell-free system was determined in vitro. Bovine brain tubulin protein (3 mg/mL) was mixed with special reaction
buffer as described in materials and method, and incubated with 2.5, 5, 10 μM cucurbitacin B, 10 μM vincristine or 10 μM paclitaxel. The
polymerization of tubulin was determined on the basis of the increase in optical density. The O.D. (340 nm) was measured each minute for up to
40 minutes at 37°C using microplate reader. Unlike paclitaxel and vincristine, treatment with cucurbitacin B in cell-free system has no effect on
tubulin density.
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suggesting that some additional factors within cells
could be involved in tubulin polymerization.
There are many cellular regulatory factors that can
affect the polymerization of microtubules. These include
microtubule-associated proteins (MAPs) such as dynein
and kinesin motor proteins, and microtubule-regulatory
proteins such as survivin, stathmin, and dynactin
[15,17,29]. Natural and synthetic compounds that target
microtubule-associated proteins are among the most
successful and widely used cancer chemotherapeutic
agents. For example, a new natural product extracted
from a soil fungus named terpendole E, has shown to
target human kinesin Eg5 leading to mitotic arrest [30].
Cucurbitacin B might also indirectly disrupt the
polymerization of microtubules via affecting some regu-
latory proteins that function on microtubule assembly.
However, the precise cooperative mediator of cucurbita-
cin B for interfering the tubulin polymerization is un-
clear and further study is needed.To identify the target molecules of cucurbitacin B in
breast cancer cells, we additionally explored proteomic
analysis. Results of 2D-PAGE, real-time RT-PCR, and
western blot analysis revealed that the expression of
nucleophosmin/B23 and c-Myc decreased markedly after
cucurbitacin B treatment. We show that cucurbitacin B
induced the translocation of nucleophosmin/B23 from the
nucleolus to nucleoplasm (Figure 6). Nucleophosmin/B23
distributes mostly in the nucleolus of the untreated cells.
It is a multifunctional phosphoprotein shuttling continu-
ously between nucleolus and cytoplasm. This protein has
an important role in controlling cellular cycling activities
related to both cell proliferation and apoptosis [31]. Previ-
ous studies showed that nucleophosmin/B23 is down-
regulated in cancer cells during drug-induced apoptosis
[32,33]. There are several anticancer drugs (i.e., actinomy-
cin D, daunomycin, camptothecin) known to induce
translocation of nucleophosmin/B23 from nucleoli to the
nucleoplasm and triggers apoptosis [34-36]. Thus, the
changes of localization and expression of nucleophosmin/
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ing that cucurbitacin B could induce nucleophosmin/B23
translocation in the same way as the other anticancer
drugs mentioned above suggests that cucurbitacin B can
induce apoptosis in breast cancer cells. Moreover, nucleo-
phosmin/B23 was reported to inhibit Eg5-mediated
microtubule depolymerization. Cells lacking nucleophos-
min/B23 exhibited a disrupted microtubule network with
a lower level of polymerized tubulin. Therefore, nucleo-
phosmin/B23 plays a protective role in microtubule
polymerization. Cucurbitacin B could down-regulate the
expression of nucleophosmin/B23, leading to disrupt the
polymerization of mitotic spindle, arrest the cell cycle at
G2/M phase and induce apoptosis.
The c-Myc has been proposed to be involved in mul-
tiple cellular functions including cell cycle regulation,
differentiation and apoptosis [37,38]. In HL60 cells, c-Myc
interacts with polymerized microtubules. This polymer-
ized protein acts as a reservoir to sequester the c-Myc
protein [39]. Pretreatment by tubulin inhibitory agents
either stabilizing or depolymerizing tubulins. This drugs
decrease c-Myc expression in human colon carcin-
oma cell HT29-D4 [40]. Thus, cucurbitacin B may
decrease the expression of c-Myc via disruption of tubu-
lin polymerization. c-Myc is able to bind promoter of
nucleophosmin/B23 at Myc-binding site and regulates
the expression of nucleophosmin/B23 [41]. Recently, ret-
inoic acid (RA) has been reported to reduce the expres-
sion of c-Myc and also affect the binding of c-Myc to
nucleophosmin/B23 expression, leading to down-regulated
expression of nucleophosmin/B23 [42]. Thus, c-Myc is one
of the factors that regulate nucleophosmin/B23 pro-
moter. In this study, we found that the expressions of
both nucleophosmin/B23 and c-Myc were decreased after
cucurbitacin B treatment. Therefore, down-regulation of
nucleophosmin/B23 during cucurbitacin B treatment may
be a consequence of the decreased expression of c-Myc
and affected binding of c-Myc to nucleophosmin/B23
promoter. Taken together, cucurbitacin B disrupts the
polymerization of microtubules, induces trafficking of
nucleophosmin/B23 from nucleolus to nucleoplasm as
well as down-regulates the expression of c-Myc and
nucleophosmin/B23.Conclusions
In conclusion, we have elucidated the novel molecular
responses for cucurbitacin B treatment. Cucurbitacin B
inhibits breast cancer cells proliferation through disrup-
tion of microtubule polymerization and induced nucleo-
phosmin/B23 translocation, causing cell cycle arrest at
G2/M phase and induced apoptosis. Therefore, cucurbi-
tacin B could be a potentially useful as a leading agent
for further anti-breast cancer research, as well as forin vivo and clinical studies aimed for breast cancer
therapy.
Additional files
Additional file 1: Extraction and isolation of cucurbitacin B. The
dried fruit fibers of T. cucumerina L. (2.72 kg) were chilled in liquid N2,
milled to small pieces and extracted successively with n-hexane, EtOAc
and MeOH in a Soxhlet extraction apparatus. The extracts were
evaporated to dryness under reduced pressure at temperature 40-45°C.
The hexane extract (greenish viscous oil, 14.9 g), the EtOAc extract
(greenish sticky solid, 83.2 g) and the MeOH extract (dark brownish
amorphous, 257.8 g) were respectively obtained. The extraction sequence
is shown in Figure 1.
Additional file 2: Figure Protein expression of nucleophosmin/B23
(Nucl./B23), STAT3, tubulin, and c-Myc were determined by western
blot analysis. MCF-7 and MDA-MB-231 were treated without or with
cucurbitacin B for 48 hrs. After incubation, total proteins were extracted
and performed western blotting to analyze the expression levels of
nucleophosmin, STAT3, tubulin, and c-Myc gene. This bar graph
represents the densitometric analyses of expression of nucleophosmin/
B23 (Nucl./B23), STAT3, tubulin, and c-Myc relative to the untreated
control. * P < 0.05 (treated vs untreated control).
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